Company profile
Immatics N.V.
NASDAQ:IMTXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Cyclophosphamide | approved | — | 8 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06946225 | phase1 | recruiting | 2025-07-25 | 2029-08-01 | Immatics US, Inc. | ACTengine® IMA203 Combined With mRNA-4203 |
| NCT03686124 | phase1_2 | recruiting | 2019-05-14 | 2028-12-01 | Immatics US, Inc. | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors |
| NCT02876510 | phase1 | completed | 2017-06-30 | 2021-09-22 | Immatics US, Inc. | ACTolog in Patients With Solid Cancers |
| NCT02149225 | phase1 | completed | 2014-10-01 | 2018-06-01 | Immatics Biotechnologies GmbH | GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients |
| NCT05359445 | phase1 | active_not_recruiting | 2022-05-19 | 2026-03-18 | Immatics Biotechnologies GmbH | IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor |
FDA applications (0)
No records yet.